Verified peer comparison

HCA vs JNJ

HCA Healthcare, Inc. compared with Johnson & Johnson. This page compares both source-verified company profiles and does not introduce an unverified price target.

HCA

HCA Healthcare, Inc.

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

JNJ

Johnson & Johnson

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

Company-specific comparison

Business exposure

HCA: Health Care Facilities

JNJ: Pharmaceuticals

Upside lens

HCA: Population growth and aging in HCA markets can support inpatient, outpatient and emergency demand. New beds, outpatient sites and service lines can capture demand in attractive local markets. Recruiting, retention and scheduling tools can reduce reliance on expensive contract labor.

JNJ: Growth from newer and expanding oncology, immunology, and neuroscience medicines can offset erosion in mature products. Higher procedure volumes and adoption of newer cardiovascular, surgery, orthopaedics, and vision technologies can support MedTech growth. Regulatory approvals, label expansions, and clinical readouts across medicine and MedTech can create additional durable revenue streams.

Risk lens

HCA: Medicare, Medicaid and commercial payment changes can lag hospital cost inflation. Nurse and physician shortages can raise wages, constrain capacity and affect care quality. Billing investigations, malpractice claims and cybersecurity incidents can create material costs.

JNJ: Pending talc claims create uncertain legal costs, potential judgments, and reputational exposure that may persist despite defense and resolution efforts. Biosimilar or generic competition, government price negotiations, and payer pressure can reduce sales and margins for key medicines. Pipeline assets and medical devices may fail trials, face approval delays, encounter safety findings, or fall short of commercial adoption expectations.